Stay updated on PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update or modification in the context of medical and healthcare-related publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:59.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of what eligibility criteria entail.
    Difference
    38%
    Check dated 2024-05-22T20:52:58.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:14:47.000Z thumbnail image

Stay in the know with updates to PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.